Clinical feasibility of non-contact in vivo conjunctival goblet cell imaging in ocular surface disease: a prospective study
In brief
Non-contact imaging quantified conjunctival goblet cells in 94% of eyes
In a prospective study, the non-contact system quantified goblet cell density in 124 of 132 eyes, with no serious adverse events. Patients with ocular surface disease had less than half the density of healthy controls, and lower counts tracked with worse surface staining and symptom scores. Repeatability, accuracy against a reference standard, and clinical usefulness remain untested.
- Journal
- The ocular surface (Q1)
- Published
- 17 November 2026
- Study design
- Cohort / observational study
- Evidence level
- Level 4, Very Low (CEBM 4)
- Authors
- Chung Young Kim, Jieun Yun, Jungbin Lee, Ga Hye Lee, Young In Yun, Mee Kum Kim, et al.
- PMID
- 43044759
- DOI
- 10.1016/j.jtos.2026.11.006
Why clinicians should know about it
- Picked for Histology (paper of the day, 20 November 2026): Quantifies conjunctival goblet-cell density using in-vivo fluorescence microscopy
Abstract
PURPOSE: To evaluate the clinical feasibility and safety of a novel non-contact in vivo imaging system for quantifying conjunctival goblet cell density (GCD) and its associations with clinical features of ocular surface disease (OSD). METHODS: In this prospective clinical trial (NCT06427629), 132 participants were enrolled, including 43 healthy controls and 89 patients with OSD: dry eye disease (DED, n = 40), Sjögren syndrome (SS, n = 27), ocular graft-versus-host disease (GVHD, n = 15), and Stevens-Johnson syndrome (SJS, n = 7). Non-contact in vivo imaging was performed after topical 0.5% moxifloxacin labeling using a high-speed extended depth-of-field fluorescence microscopy with real-time surface tracking. GCD was quantified from the inferior bulbar conjunctiva by semi-automated analysis. Clinical assessments included ocular surface staining, Schirmer I test, tear break-up time, tear matrix metalloproteinase-9 test, and Ocular Surface Disease Index (OSDI). RESULTS: GCD was successfully quantified in 124 eyes (93.9%). No serious adverse events occurred; two mild transient events resolved spontaneously. GCD was significantly lower in OSD than in healthy controls (52.8 vs. 125.0 cells/mm2; P < 0.001). Mean GCD was 52.9 cells/mm2 in DED, 51.0 in SS, 70.1 in GVHD, and 18.2 in SJS. GCD correlated negatively with corneal and conjunctival fluorescein staining, and OSDI. CONCLUSIONS: Non-contact in vivo conjunctival GC imaging is feasible and safe. Quantitative GCD assessment shows cross-sectional associations with selected ocular surface parameters. Test-retest repeatability, quantitative validity against a human reference standard, and clinical utility require further prospective evaluation.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.